MA38356A1 - Cabazitaxel et son utilisation pour le traitement des cancers de la prostate métastatiques - Google Patents

Cabazitaxel et son utilisation pour le traitement des cancers de la prostate métastatiques

Info

Publication number
MA38356A1
MA38356A1 MA38356A MA38356A MA38356A1 MA 38356 A1 MA38356 A1 MA 38356A1 MA 38356 A MA38356 A MA 38356A MA 38356 A MA38356 A MA 38356A MA 38356 A1 MA38356 A1 MA 38356A1
Authority
MA
Morocco
Prior art keywords
treatment
prostate cancer
cabazitaxel
metastatic prostate
enterocolitis
Prior art date
Application number
MA38356A
Other languages
English (en)
Inventor
Steven Neibart
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47901920&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA38356(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of MA38356A1 publication Critical patent/MA38356A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne le composé répondant à la formule suivante : (i), qui peut se trouver sous la forme d'une base ou sous la forme d'un hydrate ou d'un solvate, en combinaison avec de la prédnisone ou de la prédnisolone, pour son utilisation dans le traitement d'un cancer de la prostate métastatique réfractaire aux hormones ou résistant à la castration chez des patients qui ne risquent pas de développer des troubles gastro-intestinaux sélectionnés dans le groupe constitué de : une hémorragie et une perforation gastro-intestinales, une gastrite, une entérocolite, une entérocolite neutropénique, une colite, une occlusion intestinale, et un iléus.
MA38356A 2013-03-04 2014-03-04 Cabazitaxel et son utilisation pour le traitement des cancers de la prostate métastatiques MA38356A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13305243 2013-03-04
PCT/EP2014/054156 WO2014135524A1 (fr) 2013-03-04 2014-03-04 Cabazitaxel et son utilisation pour le traitement des cancers de la prostate métastatiques

Publications (1)

Publication Number Publication Date
MA38356A1 true MA38356A1 (fr) 2017-06-30

Family

ID=47901920

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38356A MA38356A1 (fr) 2013-03-04 2014-03-04 Cabazitaxel et son utilisation pour le traitement des cancers de la prostate métastatiques

Country Status (21)

Country Link
US (2) US20150374717A1 (fr)
EP (1) EP2964212A1 (fr)
JP (1) JP2016516673A (fr)
KR (1) KR20150123892A (fr)
CN (2) CN105073104A (fr)
AU (1) AU2014224705A1 (fr)
BR (1) BR112015021450A2 (fr)
CA (1) CA2903132A1 (fr)
CL (1) CL2015002454A1 (fr)
CR (1) CR20150442A (fr)
EA (1) EA201591622A1 (fr)
HK (1) HK1215535A1 (fr)
IL (1) IL241015A0 (fr)
MA (1) MA38356A1 (fr)
MX (1) MX2015011589A (fr)
PH (1) PH12015501900A1 (fr)
SG (1) SG11201506803XA (fr)
TN (1) TN2015000378A1 (fr)
TW (2) TW201438714A (fr)
WO (1) WO2014135524A1 (fr)
ZA (1) ZA201506310B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016113752A2 (fr) * 2015-01-12 2016-07-21 Emcure Pharmaceuticals Limited Formulation liquide de cabazitaxel
WO2022067185A1 (fr) * 2020-09-27 2022-03-31 Veru Inc. Méthodes de traitement du cancer de la prostate à effets secondaires minimes
JP2024534805A (ja) * 2021-08-17 2024-09-26 フォンダツィオーネ ペル リスティトゥート オンコロジコ ディ リチェルカ （イオエッレ） 共生細菌は前立腺がんにおいてアンドロゲン生合成を介して内分泌抵抗性を促進する
KR102685052B1 (ko) * 2023-02-15 2024-07-12 사회복지법인 삼성생명공익재단 전이성 전립선암의 호르몬 치료 저항성 예측용 신규 바이오마커 및 이의 용도

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2862340T3 (es) * 2009-10-29 2021-10-07 Sanofi Mature Ip Nuevo uso antitumoral de cabazitaxel

Also Published As

Publication number Publication date
US20150374717A1 (en) 2015-12-31
PH12015501900A1 (en) 2016-01-11
CN108354921A (zh) 2018-08-03
TW201438714A (zh) 2014-10-16
CR20150442A (es) 2015-10-07
KR20150123892A (ko) 2015-11-04
MX2015011589A (es) 2016-06-24
HK1215535A1 (zh) 2016-09-02
ZA201506310B (en) 2017-02-22
CA2903132A1 (fr) 2014-09-12
EP2964212A1 (fr) 2016-01-13
CL2015002454A1 (es) 2016-02-12
TN2015000378A1 (en) 2017-01-03
BR112015021450A2 (pt) 2017-07-18
US20180042941A1 (en) 2018-02-15
TW201827417A (zh) 2018-08-01
JP2016516673A (ja) 2016-06-09
WO2014135524A1 (fr) 2014-09-12
IL241015A0 (en) 2015-11-30
SG11201506803XA (en) 2015-09-29
AU2014224705A1 (en) 2015-09-24
CN105073104A (zh) 2015-11-18
EA201591622A1 (ru) 2016-04-29

Similar Documents

Publication Publication Date Title
FR24C1028I2 (fr) Inhibiteurs marqués de l'antigène membranaire spécifique de la prostate (psma), leur utilisation comme agents d'imagerie et agents pharmaceutiques pour le traitement du cancer de la prostate
ZA201906832B (en) Novel psma-binding agents and uses thereof
JO3606B1 (ar) معدل مستقبل الأندروجين في توليفة مع أسيتات أبراتيرون وبريدنيزون لعلاج سرطان البروستاتا
GEP20217281B (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
EA201690265A3 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
WO2015048547A3 (fr) Procédé d'utilisation de composés activant l'ampk et biomarqueurs de l'ampk
MX390878B (es) Usos medicos de antagonista de ligando 1 de muerte programada (pd-l1).
BR112017011788A2 (pt) composições anticâncer
CL2015001655A1 (es) Compuestos derivados de ftalazin-1(2h)-ona, inhibidores selectivos de la poli(adp-ribosa) polimerasa-1; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
TN2020000072A1 (en) Psma ligands for imaging and endoradiotherapy
PH12017500979A1 (en) Anticancer compositions
MX2018007844A (es) Derivado de benzopiperidina, metodo de preparacion del mismo y su uso medico del mismo.
MX375902B (es) Inhibidores de serina/treonina cinasa.
MX2017007201A (es) Composiciones anticancerigenas.
NZ739770A (en) 18f-tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer
MA38356A1 (fr) Cabazitaxel et son utilisation pour le traitement des cancers de la prostate métastatiques
EA201270606A1 (ru) Новое противоопухолевое применение кабазитаксела
ZA202301066B (en) Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer
MA41203B1 (fr) Procédés pour la préparation d'un composé diaryl-thiohydantoïne
MX2021012096A (es) Compuestos de indenilo, composiciones farmaceuticas y usos medicos del mismo.
EP3423055A4 (fr) Utilisation du trans-[tétrachlorobis(1h-indazole)ruthénate (iii)]pour le traitement d'un cancer
Pruneri et al. Core needle biopsy as a front line diagnostic approach for lymphoma patients
EP3302581A4 (fr) Agent d'imagerie diagnostique pour métastase osseuse précoce de cancer
WO2017095918A3 (fr) Procédés de traitement du cancer au moyen d'antagonistes de rspo3
MA53933A (fr) Poly-immunothérapie pour le traitement du cancer du sein triple-négatif